At a glance
ClinicalIndex Comparison RecordPhase 2Terminated· 4 enrolled
Drug / intervention
Inotuzumab Ozogamicinbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating Inotuzumab Ozogamicin for CD22 Positive and 2 related conditions. Terminated early, enrolled 4 participants across 1 site.
Signals
Trial was terminated early
Detailed Summary
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2TerminatedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartNov 2017
Primary CompletionMar 2020
TodayJul 2026
First PostedMar 29, 2017
Enrollment StartNov 30, 2017
Primary CompletionMar 11, 2020
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 9.3 years ago
Interventions
Inotuzumab Ozogamicinbiological
Given IV